CLDE225A2201
Laufzeit: 01.01.2011 - 31.12.2017
Kurzfassung
A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma
Laufzeit: 01.01.2011 - 31.12.2017
A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma
